Mark Drazner is a Cardiology physician. OpenAlex indexes 480 publications with 52,671 citations (h-index 75); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Advanced Heart Failure and Transplant Cardiology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5323 Harry Hines Blvd
Dallas, TX 753907208
Telephone
214-645-8000Provider last certified this registry record 22 Jan 2026.
Clinical trials
- American Registry of Ambulatory or Acutely Decompensated Heart Failure
Sponsor: Fundacion Clinica Valle del Lili
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.5%Beta blocker33.3%Carvedilol56%Metoprolol Succinate44%Part D≥16 patientsAngiotensin receptor-neprilysin inhibitor (ARNI)21.6%Entresto100%Part D≥14 patients+ 2 more classes in this area
Blood & clotting
19.8%Vitamin K antagonist11.1%Warfarin Sodium100%Part D<11 patientsFactor Xa inhibitor8.6%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
6.8%SGLT2 inhibitor6.8%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis
Journal of the American College of Cardiology
2024 - 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Journal of the American College of Cardiology
2022 - 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Journal of the American College of Cardiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”